Pharmagreen Biotech Inc.

Equities

PHBI

US71716C1099

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:48:33 2024-06-14 EDT			5-day change	1st Jan Change
0.0009 ^USD	-10.00%		-18.18%	+50.00%

05-20	Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
02-21	Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024

May 19, 2024 at 11:22 pm

Pharmagreen Biotech Inc. reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported sales was USD 0.001058 million compared to USD 0.000963 million a year ago. Net loss was USD 0.037955 million compared to USD 0.187982 million a year ago.
For the six months, sales was USD 0.002294 million compared to USD 0.000963 million a year ago. Net loss was USD 0.182808 million compared to USD 0.227356 million a year ago.

Latest news about Pharmagreen Biotech Inc.

Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-19	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-20	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	01-08	CI
Pharmagreen Biotech Inc. cancelled the transaction announced on November 2, 2022	11-01	CI
Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.Com and Develops Its Next Pre-Workout Formulation	23-09-05	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-19	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-14	CI
Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement Product	23-02-08	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-01-17	CI
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt	23-01-16	CI
Pharmagreen Biotech Inc. announced that it expects to receive $0.05 million in funding from JanBella Group, LLC	22-11-01	CI
Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch	22-09-08	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-17	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-16	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	22-02-22	CI
Pharmagreen Biotech Inc. completed the acquisition of Long Valley Farms LLC.	22-01-19	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	21-12-29	CI
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt	21-12-28	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-18	CI
Pharmagreen Biotech Inc. entered into memorandum of understanding to acquire Long Valley Farms LLC for $2.4 million.	21-08-11	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-24	CI
Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp Biomass	21-02-16	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	21-01-08	CI
Pharmagreen Biotech Inc. announced a financing transaction	20-10-13	CI

Chart Pharmagreen Biotech Inc.

Duration

Period

More charts

Company Profile

Pharmagreen Biotech, Inc. is a Canada-based company. The Company is engaged in developing its line of nutraceutical products, which is a blend of therapeutic plants and mushrooms. Utilizing the Company's expertise in plant genetics, its transgenic program uses the technology available to research and create nutraceuticals, and daily supplements with the potential to improve lives and address a wide variety of ailing conditions. Its nutraceutical product, MaxGenomic Supplement, comes in a bottle with 60 enteric capsules. The MaxGenomic Supplement is a proprietary blend that consists of nine medicinal mushrooms and six medical plants to help support the human mind and body. Its other nutraceutical products are in various development stages. Its subsidiaries include WFS Pharmagreen Inc, and 1155097 BC Ltd.

Sector

Biotechnology & Medical Research

Calendar

2024-09-01 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMAGREEN BIOTECH INC.	+50.00%	597K
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research